In the TROPiCS-02 study, patients with HR-positive/HER2-negative advanced breast cancer randomly assigned to receive the antibody-drug conjugate sacituzumab govitecan-hziy (vs treatment of physician’s choice) had a median progression-free survival of how many months?
